Rare Multidrug-resistant Pseudomonas aeruginosa Identified in a U.S. Deployed Service Member Following Host-nation Medical Treatment

Affiliations

05 March 2022

-

doi: 10.1093/milmed/usaa560


Abstract

Decision-making related to the utilization of host-nation medical resources in austere forward-deployed environments is complex. Clinical circumstances, local medical intelligence availability, transportation assets, uncertainty regarding standard-of-care variations, military/host-nation funding complications, and regional security concerns all factor into consideration. A case of a U.S. active duty military service member who suffered a cardiac arrest on a military base in Southwest Asia is described in this report. After return of circulation following defibrillation, he was administered thrombolytic therapy for an electrocardiogram-identified ST-elevation myocardial infarction and transported to a local host-nation cardiac hospital for emergent percutaneous coronary intervention. During his subsequent transportation back to the USA, surveillance testing identified that he was colonized with a rare strain of Pseudomonas aeruginosa, demonstrating New Delhi metallo-beta-lactamase-1 and 16S RNA methyltransferase-2 enzymes, which confer significant resistance to carbapenem and aminoglycoside antibiotics, respectively.1-3 This combination of antibiotic resistance has been reported very rarely in the medical literature and has never been reported within the deployed military health system until now. The risk of exposure to multidrug-resistant organisms was not a factor initially considered in the decision to utilize host-nation medical resources in this case, which provided lesson learned and raised new questions, for future operational medical planning.


Similar articles

Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.

Pan X, Zhao X, Song Y, Ren H, Tian Z, Liang Q, Jin Y, Bai F, Cheng Z, Feng J, Wu W.Microbiol Spectr. 2022 Feb 23;10(1):e0267821. doi: 10.1128/spectrum.02678-21. Epub 2022 Feb 23.PMID: 35196805 Free PMC article.

Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.

Juan C, Zamorano L, PĂ©rez JL, Ge Y, Oliver A; Spanish Group for the Study of Pseudomonas; Spanish Network for Research in Infectious Diseases.Antimicrob Agents Chemother. 2010 Feb;54(2):846-51. doi: 10.1128/AAC.00834-09. Epub 2009 Nov 23.PMID: 19933793 Free PMC article.

Investigating of four main carbapenem-resistance mechanisms in high-level carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.

Rostami S, Farajzadeh Sheikh A, Shoja S, Farahani A, Tabatabaiefar MA, Jolodar A, Sheikhi R.J Chin Med Assoc. 2018 Feb;81(2):127-132. doi: 10.1016/j.jcma.2017.08.016. Epub 2017 Oct 9.PMID: 29033110

Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Kanj SS, Kanafani ZA.Mayo Clin Proc. 2011 Mar;86(3):250-9. doi: 10.4065/mcp.2010.0674.PMID: 21364117 Free PMC article. Review.

Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Karakonstantis S, Kritsotakis EI, Gikas A.Infection. 2020 Dec;48(6):835-851. doi: 10.1007/s15010-020-01520-6. Epub 2020 Sep 1.PMID: 32875545 Free PMC article. Review.


KMEL References